{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06456463",
            "orgStudyIdInfo": {
                "id": "STML-401-0423"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-514660-48-00",
                    "type": "CTIS"
                },
                {
                    "id": "U1111-1290-9087",
                    "type": "OTHER",
                    "domain": "UTN"
                }
            ],
            "organization": {
                "fullName": "Stemline Therapeutics, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy",
            "officialTitle": "A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-tagraxofusp-in-combination-with-venetoclax-and-azacitidine-in-adults-with-untreated-acute-myeloid-leukemia-who-cannot-undergo-intensive-chemotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-02-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-31",
            "studyFirstSubmitQcDate": "2024-06-07",
            "studyFirstPostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stemline Therapeutics, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp, used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2. Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia"
            ],
            "keywords": [
                "CD123+",
                "Tagraxofusp",
                "Venetoclax",
                "Azacitidine"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Part 1 (randomized) will evaluate 2 dose levels of tagraxofusp in parallel. The decision to proceed to Part 2 (non-randomized) will be based upon review of cumulative data from Part 1.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 76,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 - Tagraxofusp (Dose 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive tagraxofusp in combination with venetoclax and azacitidine.",
                    "interventionNames": [
                        "Drug: Tagraxofusp",
                        "Drug: Venetoclax",
                        "Drug: Azacitidine"
                    ]
                },
                {
                    "label": "Part 1 - Tagraxofusp (Dose 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive tagraxofusp in combination with venetoclax and azacitidine.",
                    "interventionNames": [
                        "Drug: Tagraxofusp",
                        "Drug: Venetoclax",
                        "Drug: Azacitidine"
                    ]
                },
                {
                    "label": "Part 2 - Tagraxofusp (Selected Dose)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive tagraxofusp in combination with venetoclax and azacitidine.",
                    "interventionNames": [
                        "Drug: Tagraxofusp",
                        "Drug: Venetoclax",
                        "Drug: Azacitidine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tagraxofusp",
                    "description": "Tagraxofusp will be administered by intravenous infusion.",
                    "armGroupLabels": [
                        "Part 1 - Tagraxofusp (Dose 1)",
                        "Part 1 - Tagraxofusp (Dose 2)",
                        "Part 2 - Tagraxofusp (Selected Dose)"
                    ],
                    "otherNames": [
                        "Tag"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Venetoclax",
                    "description": "Venetoclax will be administered as an oral tablet.",
                    "armGroupLabels": [
                        "Part 1 - Tagraxofusp (Dose 1)",
                        "Part 1 - Tagraxofusp (Dose 2)",
                        "Part 2 - Tagraxofusp (Selected Dose)"
                    ],
                    "otherNames": [
                        "Ven"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Azacitidine",
                    "description": "Azacitidine will be administered subcutaneously or by intravenous infusion.",
                    "armGroupLabels": [
                        "Part 1 - Tagraxofusp (Dose 1)",
                        "Part 1 - Tagraxofusp (Dose 2)",
                        "Part 2 - Tagraxofusp (Selected Dose)"
                    ],
                    "otherNames": [
                        "Aza"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 2: Number of Participants Achieving a Best Overall Response (BOR) of Complete Remission (CR)",
                    "timeFrame": "Cycles 1-4 (up to 112 days; 28 days/cycle)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1 and 2: Number of Participants Achieving a BOR of CR",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Time to First CR",
                    "description": "The time to first CR will be defined as the time from randomization (Cycle 1, Day 1) to the date of first documented CR.",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Duration of Response",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants Achieving a BOR of CR, CR with Incomplete Hematologic Recovery (CRi), or CR with Partial Hematologic Recovery (CRh)",
                    "timeFrame": "Cycles 1-4 (up to 112 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Time to First Composite CR",
                    "description": "The time to first composite CR will be defined as the time from randomization (Cycle 1, Day 1) to the date of first documented CR, CRi, or CRh.",
                    "timeFrame": "Cycles 1-4 (up to 112 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants Achieving a BOR of CR or CRi",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Time to first CR/CRi",
                    "description": "The time to first CR/CRi will be defined as the time from randomization (Cycle 1, Day 1) to the date of first documented CR or CRi.",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Event-free Survival (EFS)",
                    "description": "EFS will be defined as the time from the date of randomization (Cycle 1, Day 1) until the date of treatment failure, hematologic relapse after CR/CRi/CRh, or death from any cause, whichever occurs first.",
                    "timeFrame": "Up to approximately 6 years"
                },
                {
                    "measure": "Parts 1 and 2: CR with Minimal Residual Disease (MRD) Negative",
                    "description": "Defined as the number of participants with a presence of marrow MRD of less than 0.01% at the time of CR.",
                    "timeFrame": "Cycles 1-6 (up to 168 days; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants Who Bridged to Stem Cell Transplant (SCT) Through Study Treatment",
                    "timeFrame": "Up to approximately 6 years"
                },
                {
                    "measure": "Parts 1 and 2: Plasma Concentration of Free Tagraxofusp, Venetoclax, and Azacitidine",
                    "timeFrame": "Predose, up to 8 hours post dose (Days 4, 5, 6, 7, 14; Cycles 1-6; 28 days/cycle)"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants With Serum Anti-drug Antibodies for Tagraxofusp, Venetoclax, and Azacitidine",
                    "timeFrame": "Day 4 of each cycle (each cycle is 28 days) up to the end of study (approximately 6 years)"
                },
                {
                    "measure": "Parts 1 and 2: Exposure-response of Free Tagraxofusp When Administered in Combination with Venetoclax and Azacitidine",
                    "description": "The exposure-response relationship will be assessed utilizing the CR rate/composite CR rate and the number of participants experiencing adverse events of interest. This model-based analysis will be conducted to compare the exposure and response of free tagraxofusp, venetoclax, and azacitidine with venetoclax and azacitidine. Results will be reported as percent probability, wherein changes in the percent probability would indicate corresponding changes in the response rates with changes in exposure.",
                    "timeFrame": "Up to approximately 6 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Histologically confirmed newly diagnosed AML with bone marrow blast count \u226520%.\n* Participant has any level of CD123 expression on blasts determined centrally by flow cytometry.\n* For participants between 60 and 74 years of age, 1 of the following comorbidities is required:\n\n  * Eastern Cooperative Oncology Group (ECOG) Score of 2 or 3.\n  * Diffusing capacity of lung for carbon monoxide of \u226465% or forced expiratory volume of 1 second \u226465%.\n  * Creatinine clearance \u226530 to \\<45 milliliters/minute.\n  * Moderate hepatic impairment with total bilirubin \\>1.5 to \u22643.0 x upper limit of normal.\n  * Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Sponsor and Medical Monitor prior to enrollment.\n* ECOG performance status:\n\n  * If \u226575 years of age, ECOG 0 to 2\n  * If \u226560 to 74 years of age, ECOG 0 to 3\n\nKey Exclusion Criteria:\n\n* Participant has received prior therapy for AML.\n* Willing and able to receive standard induction therapy.\n* Treatment for an antecedent hematologic disease with any of the following:\n\n  * A hypomethylating agent, venetoclax, tagraxofusp, purine analogue, cytarabine, intensive chemotherapy.\n  * Chimeric antigen receptor-T therapy or other experimental therapies.\n* AML with central nervous system involvement.\n\nNote: Other inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "60 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stemline Trials",
                    "role": "CONTACT",
                    "phone": "1-877-332-7967",
                    "email": "clinicaltrials@menarinistemline.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Los Angeles",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gary Schiller, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute (DFCI)",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrew A Lane, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amir Fathi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Washington University - Siteman Cancer Center",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Mt. Sinai - Ruttenberg Treatment Center",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Douglas A Tremblay, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic Foundation",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hetty E Carraway, MD, MBA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Baylor Scott & White Health",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Moshe Yair Levy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Naval G Daver, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Hunstman Cancer Institute",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84132",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Srinivas K Tantravahi, MBBS, MRCP",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001374",
                    "term": "Azacitidine"
                },
                {
                    "id": "C000579720",
                    "term": "Venetoclax"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M249656",
                    "name": "Venetoclax",
                    "asFound": "0.1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "asFound": "Pilot Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}